Merck acquires Swiss firm OncoEthix
December 19, 2014Sales and Marketing Cancer, FDA, Merck, OTX015, cubist, keytruda, oncoethix, pembrolizumab
Hot on the heals of its Cubist buyout Merck has confirmed the acquisition of OncoEthix, a Swiss based firm which …
Roche dealt with two late-stage blows
December 19, 2014Sales and Marketing Alzheimer's, Alzheimer’s, Cancer, Kadcyla, Perjeta, Roche, Xeloda, trastuzumab emtansine
Swiss giant Roche’s breast cancer treatment Kadcyla has failed to meet its primary endpoint and its investigational Alzheimer’s treatment trial …
GSK shingles vaccine on form
December 19, 2014Sales and Marketing GSK, HZ/su, Merck, Vaccine, Zostavax, shingles
GlaxoSmithKline will be celebrating following the successful Phase III study of its shingles vaccine HZ/su that has met its primary …
NHS not au fait with mobile-savvy patients
December 19, 2014Medical Communications, Sales and Marketing NHS, app, digital, health, mobile, smartphones, wearables
The NHS is failing to keep up with its digital generation of patients, a recent study has found. Despite a …
Takeda takes senior head from Sanofi
December 19, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Sanofi, Takeda, andrew plump
Dr Andrew Plump will be joining Takeda in February from Sanofi to lead its global R&D operations as chief medical …
New Lyrica formulation effective in trials
December 19, 2014Sales and Marketing HIV, Lyrica, Pfizer, pain, pregabalin, shingles
Pfizer has reported positive Phase III results for a new formulation of its painkiller Lyrica. In the study, a controlled-release …
Humira biosimilar released in India
December 18, 2014Research and Development, Sales and Marketing Humira, India, Zydus Cadila, anti-inflammatory, arthritis, bioscience
Indian firm Zydus Cadila has launched the first biosimilar of AbbVie’s anti-inflammatory medicine Humira, the world’s biggest-selling drug. Used as …
Government plans £6 billion precision medicine strategy
December 18, 2014Research and Development, Sales and Marketing ABPI, Cell Therapy Catapult, Ebola, George Osborne, UK, government
The government has committed to a £6 billion investment in scientific research and development as part of its science and …
Lundbeck scraps stroke drug
December 18, 2014Research and Development, Sales and Marketing AIS, DIAS, Lundbeck, acute ischemic stroke, desmoteplase, stroke
Lundbeck has stopped development of its investigational stroke drug desmoteplase following disappointing results from its Phase III studies. The DIAS-3 …
AstraZeneca ovarian cancer drug approved in Europe
December 18, 2014Sales and Marketing AstraZeneca, BRCA, Cambridge, Cancer, FDA, lynparza, olaparib, ovarian
The European Commission has approved AstraZeneca’s Lynparza for the treatment of advanced BRCA-mutated ovarian cancer. Lynparza (olaparib) has been approved …
Roche adds two to its board
December 18, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bernard Poussot, Richard Lift, Roche, Sanofi
Roche intends to grow at its March annual general meeting via the election of Bernard Poussot and Richard Lift who …
Roche wins drug discovery award for Gazyvaro
December 18, 2014Sales and Marketing BPS, British Pharmacological Society, GSK, Gazyvaro, Roche, mekinist
Roche has been named the winner of the 2015 Drug Discover of the Year award by the British Pharmacological Society …
Janssen Healthcare Innovation two-time finalists at eyeforpharma Barcelona Awards
December 17, 2014Janssen Healthcare Innovation’s Care4Today programme is set to take two of the highest honours at the 2015 eyeforpharma Barcelona Awards …
PM Society names pharma prize finalists
December 17, 2014Medical Communications, Sales and Marketing GSK, Mundipharma, Shire, VCCP Health, digital awards, pm society
The finalists for the PM Society Awards have been announced today as pharma and med comms agencies gear up to …
Lilly’s lung cancer drug sees FDA approval
December 17, 2014Sales and Marketing BMS, Cancer, FDA, NSCLC, cyramza, docetaxel, lilly, opdivo, ramucirumab
Eli Lilly’s lung cancer drug Cyramza (ramucirumab) has been shown the green light by the US Food and Drug Administration …
Apps & Digital Resources vie for top honour at eyeforpharma Barcelona Awards
December 17, 2014Two thirds of the finalists for the ‘Most Valuable Patient Initiative’ in the 2015 eyeforpharma Barcelona Awards have used interactive …
Big pharma spent $112 billion on R&D in 2013
December 17, 2014Research and Development, Sales and Marketing Merck, Pfizer, R&D, Roche, data, global data, research
The top 30 pharma companies spent a combined total of $112 billion on research and development last year. Calculated to …
Adaptive licensing could ‘transform industry’
December 17, 2014Research and Development, Sales and Marketing Clinical Pharmacology & Therapeutics, EFPIA, EMA, MHRA, adaptive licesning
Drug regulators should switch to adaptive pathways as the preferred approach to bringing future new medicines to patients, according to …
GSK Ebola vaccine gets EU support
December 17, 2014Research and Development, Sales and Marketing EC, EU, Ebola, Europe, GSK, Merck, Takeda, Vaccine, WHO, johnson
A newly-formed European consortium is to help advance the development of GlaxoSmithKline’s promising Ebola vaccine. The consortium is backed by …
Cell Therapy Catapult to build £55 million bioscience campus
December 17, 2014Research and Development, Sales and Marketing Cell Therapy Catapult, UK, bioscience, research, stevenage
UK firm The Cell Therapy Catapult has chosen to build a £55 million state-of-the-art cell therapy manufacturing centre in Stevenage. …
Latest content
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations
Alcami appoints Will Isom to lead laboratory services sales
